Concomitant Medications for Progressive Supranuclear Palsy: A Secondary Analysis of a Randomized Clinical Trial

Research Letter

January 22, 2024

Author Affiliations Article Information

¹Departments of Molecular and Cellular Biology and Statistics, Harvard University, Cambridge, Massachusetts
²Population Health Research Institute, Center for Health Care Research and Policy, MetroHealth Medical Center, School of Medicine, Case Western Reserve University, Cleveland, Ohio
³Edmond J. Safra Program in Parkinson’s Disease, Rossy Progressive Supranuclear Palsy Centre, Movement Disorders Clinic, Krembil Brain Institute, Toronto Western Hospital, University Health Network and Division of Neurology, University of Toronto, Toronto, Ontario, Canada
⁴Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey
⁵Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland
⁶Memory and Aging Center, Department of Neurology, University of California, San Francisco
⁷Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

JAMA Neurol. 2024;81(3):295-297. doi:10.1001/jamaneurol.2023.5215